Unknown

Dataset Information

0

Agreement in risk prediction between the 21-gene recurrence score assay (Oncotype DX®) and the PAM50 breast cancer intrinsic Classifier™ in early-stage estrogen receptor-positive breast cancer.


ABSTRACT: PURPOSE: To compare risk assignment by PAM50 Breast Cancer Intrinsic Classifier™ and Oncotype DX_Recurrence Score (RS) in the same population. METHODS: RNA was extracted from 151 estrogen receptor (ER)+ stage I-II breast cancers and gene expression profiled using PAM50 "intrinsic" subtyping test. RESULTS: One hundred eight cases had complete molecular information; 103 (95%) were classified as luminal A (n = 76) or luminal B (n = 27). Ninety-two percent (n = 98) had a low (n = 59) or intermediate (n = 39) RS. Among luminal A cancers, 70% had low (n = 53) and the remainder (n = 23) had an intermediate RS. Among luminal B cancers, nine were high (33%) and 13 were intermediate (48%) by the RS. Almost all cancers with a high RS were classified as luminal B (90%, n = 9). One high RS cancer was identified as basal-like and had low ER/ESR1 and low human epidermal growth factor receptor 2 (HER2) expression by quantitative polymerase chain reaction in both assays. The majority of low RS cases were luminal A (83%, n = 53). Importantly, half of the intermediate RS cancers were re-categorized as low risk luminal A subtype by PAM50. CONCLUSION: There is good agreement between the two assays for high (i.e., luminal B or RS > 31) and low (i.e., luminal B or RS < 18) prognostic risk assignment but PAM50 assigns more patients to the low risk category. About half of the intermediate RS group was reclassified as luminal A by PAM50.

SUBMITTER: Kelly CM 

PROVIDER: S-EPMC3336833 | biostudies-other | 2012

REPOSITORIES: biostudies-other

altmetric image

Publications

Agreement in risk prediction between the 21-gene recurrence score assay (Oncotype DX®) and the PAM50 breast cancer intrinsic Classifier™ in early-stage estrogen receptor-positive breast cancer.

Kelly Catherine M CM   Bernard Philip S PS   Krishnamurthy Savitri S   Wang Bailiang B   Ebbert Mark T W MT   Bastien Roy R L RR   Boucher Kenneth M KM   Young Elliana E   Iwamoto Takayuki T   Pusztai Lajos L  

The oncologist 20120314 4


<h4>Purpose</h4>To compare risk assignment by PAM50 Breast Cancer Intrinsic Classifier™ and Oncotype DX_Recurrence Score (RS) in the same population.<h4>Methods</h4>RNA was extracted from 151 estrogen receptor (ER)+ stage I-II breast cancers and gene expression profiled using PAM50 "intrinsic" subtyping test.<h4>Results</h4>One hundred eight cases had complete molecular information; 103 (95%) were classified as luminal A (n = 76) or luminal B (n = 27). Ninety-two percent (n = 98) had a low (n =  ...[more]

Similar Datasets

| S-EPMC7881187 | biostudies-literature
| S-EPMC5827461 | biostudies-other
| S-EPMC9469592 | biostudies-literature
| S-EPMC8442227 | biostudies-literature
| S-EPMC6763428 | biostudies-literature
| S-EPMC5387031 | biostudies-literature
| S-EPMC7643688 | biostudies-literature
| S-EPMC7019096 | biostudies-literature
| S-EPMC7380510 | biostudies-literature
| S-EPMC6937305 | biostudies-literature